{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:02:59Z","timestamp":1792605779578,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hereditary transthyretin (hATTR) amyloidosis is a rare, systemic, progressive, and life-threatening disease in which transthyretin proteins misfold and aggregate as insoluble amyloid deposits, disrupting nervous, cardiac, gastrointestinal, and other organ tissues. There are limited available data about the experience of patients living with hATTR amyloidosis. This study used a qualitative, non-interventional design to explore the humanistic burden of hATTR amyloidosis from the patient\u2019s perspective.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fourteen adults with hATTR amyloidosis, recruited from a patient advocacy group or an academic clinical center, participated in individual semi-structured interviews either in person or by telephone. Patients were asked to describe their experiences living with the condition, including symptoms and disease-related impacts on functioning and well-being, work, and activities of daily living (ADLs). Interviews were transcribed verbatim and analyzed for key concepts using a grounded theory approach.<\/jats:p>\n                <jats:p>Patients described many symptoms of hATTR amyloidosis, particularly those associated with peripheral neuropathy such as pain, numbness, weakness, and paresthesia. Symptoms of autonomic neuropathy, such as gastrointestinal dysfunction, and symptoms related to cardiac dysfunction were also common. Worsening symptoms, especially those impacting patients\u2019 ability to walk or use their hands, often led to a loss of autonomy and an inability to work or perform ADLs. Disease-related disability also interfered with patients\u2019 participation in social activities, and contributed to feelings of fear, frustration, or sadness.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The impacts of hATTR amyloidosis were profound for the patients interviewed for this study. They described a sense of loss as their condition progressed and impacted them physically, emotionally, and socially. Patients\u2019 reports of symptoms and impacts of hATTR amyloidosis illustrate the complex and varied manifestations of this disease. The progression of symptoms and increasing impacts of hATTR amyloidosis also highlight the need for an earlier diagnosis and effective clinical intervention to preserve patients\u2019 functioning and well-being.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41687-020-00273-y","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T16:03:46Z","timestamp":1610035426000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Patient-reported burden of hereditary transthyretin amyloidosis on functioning and well-being"],"prefix":"10.1186","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9118-0673","authenticated-orcid":false,"given":"Andrew","family":"Lovley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer D.","family":"Guthrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishali","family":"Sanchorawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle K.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"key":"273_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1750-1172-8-31","volume":"8","author":"Y Ando","year":"2013","unstructured":"Ando, Y., Coelho, T., Berk, J. L., et al. (2013). Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet Journal of Rare Diseases, 8, 31. https:\/\/doi.org\/10.1186\/1750-1172-8-31.","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"21","key":"273_CR2","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","volume":"66","author":"MA Gertz","year":"2015","unstructured":"Gertz, M. A., Benson, M. D., Dyck, P. J., et al. (2015). Diagnosis, prognosis, and therapy of transthyretin amyloidosis. Journal of the American College of Cardiology, 66(21), 2451\u20132466. https:\/\/doi.org\/10.1016\/j.jacc.2015.09.075.","journal-title":"Journal of the American College of Cardiology"},{"issue":"5","key":"273_CR3","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1055\/s-0039-1688994","volume":"39","author":"M Kaku","year":"2019","unstructured":"Kaku, M., & Berk, J. (2019). Neuropathy associated with systemic amyloidosis. Seminars in Neurology, 39(5), 578\u2013588. https:\/\/doi.org\/10.1055\/s-0039-1688994.","journal-title":"Seminars in Neurology"},{"issue":"8","key":"273_CR4","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3109\/07853890.2015.1068949","volume":"47","author":"PN Hawkins","year":"2015","unstructured":"Hawkins, P. N., Ando, Y., Dispenzeri, A., Gonzalez-Duarte, A., Adams, D., & Suhr, O. B. (2015). Evolving landscape in the management of transthyretin amyloidosis. Annals of Medicine, 47(8), 625\u2013638. https:\/\/doi.org\/10.3109\/07853890.2015.1068949.","journal-title":"Annals of Medicine"},{"issue":"1","key":"273_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1185\/03007995.2012.754348","volume":"29","author":"T Coelho","year":"2013","unstructured":"Coelho, T., Maurer, M. S., & Suhr, O. B. (2013). THAOS - the Transthyretin amyloidosis outcomes survey: Initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Current Medical Research and Opinion, 29(1), 63\u201376. https:\/\/doi.org\/10.1185\/03007995.2012.754348.","journal-title":"Current Medical Research and Opinion"},{"issue":"7 Suppl","key":"273_CR6","first-page":"S107","volume":"23","author":"MA Gertz","year":"2017","unstructured":"Gertz, M. A. (2017). Hereditary ATTR amyloidosis: Burden of illness and diagnostic challenges. The American Journal of Managed Care, 23(7 Suppl), S107\u2013S112.","journal-title":"The American Journal of Managed Care"},{"key":"273_CR7","doi-asserted-by":"publisher","unstructured":"Stewart, M., Shaffer, S., Murphy, B., et al. (2018). Characterizing the high disease burden of transthyretin amyloidosis for patients and caregivers. Neurology and Therapy. https:\/\/doi.org\/10.1007\/s40120-018-0106-z.","DOI":"10.1007\/s40120-018-0106-z"},{"issue":"2","key":"273_CR8","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/mus.26515","volume":"60","author":"A Yarlas","year":"2019","unstructured":"Yarlas, A., Gertz, M. A., Dasgupta, N. R., et al. (2019). Burden of hereditary transthyretin amyloidosis on quality of life. Muscle & Nerve, 60(2), 169\u2013175. https:\/\/doi.org\/10.1002\/mus.26515.","journal-title":"Muscle & Nerve"},{"issue":"1","key":"273_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","volume":"140","author":"T Lane","year":"2019","unstructured":"Lane, T., Fontana, M., Martinez-Naharro, A., et al. (2019). Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation., 140(1), 16\u201326. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038169.","journal-title":"Circulation."},{"issue":"7","key":"273_CR10","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/nrcardio.2010.67","volume":"7","author":"C Rapezzi","year":"2010","unstructured":"Rapezzi, C., Quarta, C. C., Riva, L., et al. (2010). Transthyretin-related amyloidoses and the heart: A clinical overview. Nature Reviews. Cardiology, 7(7), 398\u2013408. https:\/\/doi.org\/10.1038\/nrcardio.2010.67.","journal-title":"Nature Reviews. Cardiology"},{"issue":"Suppl 1","key":"273_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-10-S1-P58","volume":"10","author":"D Adams","year":"2015","unstructured":"Adams, D., Amitay, O., & Coelho, T. (2015). Patients with hereditary ATTR amyloidosis experience an increasing burden of illness as the disease progresses. Orphanet Journal of Rare Diseases, 10(Suppl 1), P58. https:\/\/doi.org\/10.1186\/1750-1172-10-S1-P58.","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"7","key":"273_CR12","doi-asserted-by":"publisher","first-page":"A436","DOI":"10.1016\/j.jval.2016.09.518","volume":"19","author":"RN Denoncourt","year":"2016","unstructured":"Denoncourt, R. N., Adams, D., Gonzalez-Duarte, A., et al. (2016). Burden of illness for patients with hereditary ATTR amyloidosis with polyneuropathy begins with symptom onset and increases with disease progression. Value in Health, 19(7), A436. https:\/\/doi.org\/10.1016\/j.jval.2016.09.518.","journal-title":"Value in Health"},{"key":"273_CR13","volume-title":"Constructing grounded theory: A practical guide through qualitative analysis","author":"K Charmaz","year":"2016","unstructured":"Charmaz, K. (2016). Constructing grounded theory: A practical guide through qualitative analysis. London: SAGE Publications, Inc."},{"issue":"7","key":"273_CR14","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jval.2017.11.014","volume":"21","author":"DM Turner-Bowker","year":"2018","unstructured":"Turner-Bowker, D. M., Lamoureaux, R. E., Stokes, J., et al. (2018). Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development. Value in Health, 21(7), 839\u2013842. https:\/\/doi.org\/10.1016\/j.jval.2017.11.014.","journal-title":"Value in Health"},{"issue":"1","key":"273_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/1744987117741667","volume":"23","author":"A Assarroudi","year":"2018","unstructured":"Assarroudi, A., Heshmati Nabavi, F., Armat, M. R., Ebadi, A., & Vaismoradi, M. (2018). Directed qualitative content analysis: The description and elaboration of its underpinning methods and data analysis process. Journal of Research in Nursing, 23(1), 42\u201355. https:\/\/doi.org\/10.1177\/1744987117741667.","journal-title":"Journal of Research in Nursing"},{"key":"273_CR16","volume-title":"Basics of qualitative research: Techniques and procedures for developing grounded theory. Fourth","author":"JM Corbin","year":"2015","unstructured":"Corbin, J. M., & Strauss, A. (2015). Basics of qualitative research: Techniques and procedures for developing grounded theory. Fourth. Thousand Oaks: SAGE Publications, Inc."},{"issue":"1","key":"273_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/jns.12153","volume":"21","author":"I Concei\u00e7\u00e3o","year":"2016","unstructured":"Concei\u00e7\u00e3o, I., Gonz\u00e1lez-Duarte, A., Obici, L., et al. (2016 Mar). \u201cRed-flag\u201d symptom clusters in transthyretin familial amyloid polyneuropathy. Journal of the Peripheral Nervous System, 21(1), 5\u20139.","journal-title":"Journal of the Peripheral Nervous System"},{"key":"273_CR18","volume-title":"Advancing amyloidosis: A research roadmap. [white paper]","author":"Amyloidosis Research Consortium","year":"2019","unstructured":"Amyloidosis Research Consortium (2019). Advancing amyloidosis: A research roadmap. [white paper]."},{"key":"273_CR19","unstructured":"Broderick L, Vera Llonch M, O\u2019Connor M, et al. Results from concept elicitation interviews with experts to support the development of an international, disease-specific PRO in transthyretin amyloidosis (ATTR). Oral presentation at: the 27th Annual Conference of the International Society for Quality of Life Research; October, 2020; Virtual."}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-020-00273-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s41687-020-00273-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-020-00273-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T17:38:06Z","timestamp":1610041086000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-020-00273-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["273"],"URL":"https:\/\/doi.org\/10.1186\/s41687-020-00273-y","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"assertion":[{"value":"14 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol, interview guide, informed consent form, and recruitment flyers were approved by the New England Institutional Review Board. All patients provided written informed consent to participate in recorded interviews.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AL, KR, MKW are full-time employees of QualityMetric Incorporated, LLC, and received research funding from Akcea Therapeutics to conduct the study. MP is a full-time employee of the study sponsor, Akcea Therapeutics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}